| |
|
|
|
PROFILE
Callisto is a biopharmaceutical company focused on the
development of drugs to treat multiple myeloma, other
cancers and osteolytic bone disease. Callisto’s lead drug
candidate, Atiprimod, is a small-molecule, orally available
compound with anti-proliferative and anti-angiogenic activity.
Atiprimod successfully completed Phase I clinical trials
in rheumatoid arthritis patients and was found to be
well-tolerated with no severe side effects.
Callisto submitted an IND in
September 2003 to take
Atiprimod into a Phase I/IIa clinical trial in multiple myeloma
patients. This trial is anticicated to begin December 2003. Atiprimod
is also being evaluated as an agent to treat osteolytic bone disease.
In collaboration with the National Cancer Institute, Atiprimod
is also being evaluated for
the treatment of other cancers.
Callisto has other innovative technology platforms
focused on the development of an analog of the human
intestinal hormone, uroguanylin, to treat colon cancer, and
broad-spectrum drug candidates to protect against
staphylococcal and streptococcal toxins, potential
bioweapons that could be used in acts of bioterrorism.
|
|
|
|
|
